Any grade adverse events more common in the combined rilotumumab group than in the placebo group included haematological adverse events ( neutropenia in @ -LSB- @ % -RSB- of @ patients vs @ -LSB- @ % -RSB- of @ patients ; anaemia in @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ; and thrombocytopenia in nine -LSB- @ % -RSB- vs none ) , peripheral oedema ( @ -LSB- @ % -RSB- vs three -LSB- @ % -RSB- ) , and venous thromboembolism ( @ -LSB- @ % -RSB- vs five -LSB- @ % -RSB- ) .